Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models

American Journal of Translational Research

Volumn 3, Issue 1, 2011, Pages 8-27

  Lu, Yan ^a,e   Liu, Pengyuan ^a,e   Wen, Weidong ^a   Grubbs, Clinton J ^b   Townsend, Reid R ^c   Malone, James P ^c   Lubet, Ronald A ^d   You, Ming ^a,e  

^a USA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

And cross species comparison; Gene expression; Human bladder cancer; Proteomics; Rodent models

Indexed keywords

CARCINOGEN; HYPOXIA INDUCIBLE FACTOR 1; MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXA1 GENE; ANXA2 GENE; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CA2 GENE; CANCER MODEL; CCNB2 GENE; CNN1 GENE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FISCHER 344 RAT; FMO5 GENE; GENE EXPRESSION REGULATION; GENETIC CONSERVATION; GENOME; HUMAN; HUMAN TISSUE; ITIH5 GENE; KIF20A GENE; KRT14 GENE; KRT18 GENE; LDHA GENE; LDHB GENE; LGALS4 GENE; MALE; MYH11 GENE; MYL9 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PCP4 GENE; PDLIM3 GENE; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; RODENT; RRM2 GENE; SERPINA1 GENE; SPECIES COMPARISON; TOP2A GENE; UNINDEXED SEQUENCE; UPREGULATION; VALIDATION PROCESS;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 78650204545     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; caac.20006.
2. Becci PJ, Thompson HJ, Strum JM, Brown CC, Sporn MB and Moon RC. N-Butyl-N-(4-Hydroxybutyl)nitrosamine-induced Urinary Bladder Cancer in C57BL/6 x DBA/2 F1 Mice as a Useful Model for Study of Chemoprevention of Cancer with Retinoids. Cancer Res 1981; 41: 927-932.
3. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL and Seibert K. Celecoxib Inhibits N-Butyl-N-(4-hydroxybutyl)- nitrosamine-induced Urinary Bladder Cancers in Male B6D2F1 Mice and Female Fischer-344 Rats. Cancer Res 2000; 60: 5599-5602.
4. Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodman DG, Brown CC and Sporn MB. 13-cis-Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Science 1977; 198: 743-744.
5. McCormick DL, Ronan SS, Becci PJ and Moon RC. Influence of total dose and dose schedule on induction of urinary bladder cancer in the mouse by N-butyl-N-(4-hydroxy-butyl)nitrosamine. Carcinogenesis 1981; 2: 251-254.
6. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF and Sigman CC. Chemoprevention of OH -BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis 1993; 14: 1487-1489.
7. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
8. Bredemeyer AJ, Lewis RM, Malone JP, Davis AE, Gross J, Townsend RR and Ley TJ. A proteomic approach for the discovery of protease substrates. Proc Natl Acad Sci U S A 2004; 101: 11785-11790.
9. King JB, Gross J, Lovly CM, Rohrs H, Piwnica-Worms H and Townsend RR. Accurate massdriven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal Chem 2006; 78: 2171-2181.
10. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K and Orntoft TF. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64: 4040-4048.
11. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F and Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778-789.
12. Strimmer K. A unified approach to false discovery rate estimation. BMC Bioinformatics 2008; 9: 303.
13. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D and Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
14. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-15550.
15. Elledge SJ, Zhou Z and Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992; 17: 119-123.
16. Torrents E, Aloy P, Gibert I and Rodriguez-Trelles F. Ribonucleotide reductases: divergent evolution of an ancient enzyme. J Mol Evol 2002; 55: 138-152.
17. Herrick J and Sclavi B. Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage. Mol Microbiol 2007; 63: 22-34.
18. Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X, Liu X, Zhou B and Yen Y. verexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer 2009; 8: 11.
19. Luo K, Yuan J, Chen J and Lou Z. Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol 2009; 11: 204-210.
20. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, Ching AK, Tong JH, Ng HK, Johnson PJ and To KF. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009; 124: 644-652.
21. Baiocchi GL, Villanacci V, Rossi E, Gheza F, Portolani N and Giulini SM. HER-2/neu and topoisomerase-II-alpha expression and genic amplification in pancreatic adenocarcinoma. Dig Dis Sci 2009; 54: 2049-2051.
22. Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Argani P, Epstein JI, Garvin AJ, Cousi R, Schaeffer EM, Pavlovich C and Netto GJ. Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol 2009; 182: 735-740.
23. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Konsgen D, Lage H, Weichert W, Noske A, Budczies J, Muller BM, Buckendahl AC, Roske A, Eldin Elwali N, Dietel M and Denkert C. Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol 2009; 22: 579-588.
24. Wang YH, Takanashi M, Tsuji K, Tanaka N, Shiseki M, Mori N and Motoji T. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients. Leuk Res 2009; 33: 902-907.
25. Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP, Sheahan K, Leahy DT, Mulcahy HE and O'Sullivan JN. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett 2009; 276: 228-238.
26. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J and Liu T. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008; 8: 363.
27. Shvero J, Koren R, Shvili I, Yaniv E, Sadov R and Hadar T. Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables. Am J Clin Pathol 2008; 130: 934-939.
28. Bellanger S, de Gramont A and Sobczak-Thepot J. Cyclin B2 suppresses mitotic failure and DNA re-replication in human somatic cells knocked down for both cyclins B1 and B2. Oncogene 2007; 26: 7175-7184.
29. Yu D, Cozma D, Park A and Thomas-Tikhonenko A. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci 2005; 1059: 145-159.
30. Koss LG. Tumors of the urinary bladder. In: Firminger HI, editors. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1975. p.
31. Herman CJ, Vegt PD, Debruyne FM, Vooijs GP and Ramaekers FC. Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4-hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression. Am J Pathol 1985; 120: 419-426.